Repligen Co. (NASDAQ:RGEN) hit a new 52-week high during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $155.27 and last traded at $148.80, with a volume of 220748 shares trading hands. The stock had previously closed at $138.78.

The biotechnology company reported $0.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.14. Repligen had a net margin of 10.23% and a return on equity of 5.99%. The business had revenue of $87.46 million during the quarter, compared to analyst estimates of $78.11 million.

RGEN has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $151.00 price target (up from $143.00) on shares of Repligen in a report on Tuesday, June 30th. Stifel Nicolaus lifted their price objective on shares of Repligen from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, May 27th. Craig Hallum lifted their price objective on shares of Repligen from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. ValuEngine downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research report on Friday, May 1st. Finally, BidaskClub upgraded shares of Repligen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 25th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $136.67.

In other Repligen news, VP Ralf Kuriyel sold 8,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $127.80, for a total transaction of $1,022,400.00. Following the sale, the vice president now directly owns 32,524 shares in the company, valued at approximately $4,156,567.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Karen A. Dawes sold 18,705 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $115.20, for a total transaction of $2,154,816.00. Following the sale, the director now owns 116,762 shares in the company, valued at $13,450,982.40. The disclosure for this sale can be found here. Insiders have sold a total of 92,264 shares of company stock worth $12,168,083 over the last 90 days. 1.70% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the business. Copper Rock Capital Partners LLC raised its position in shares of Repligen by 3,515.5% during the 2nd quarter. Copper Rock Capital Partners LLC now owns 7,031,327 shares of the biotechnology company’s stock worth $253,508,000 after buying an additional 6,836,851 shares in the last quarter. State Street Corp raised its holdings in shares of Repligen by 2.1% in the 1st quarter. State Street Corp now owns 1,588,648 shares of the biotechnology company’s stock worth $153,368,000 after purchasing an additional 32,598 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 6.1% in the 1st quarter. Conestoga Capital Advisors LLC now owns 1,342,839 shares of the biotechnology company’s stock worth $129,638,000 after purchasing an additional 77,505 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Repligen by 497.4% in the 1st quarter. Alliancebernstein L.P. now owns 981,043 shares of the biotechnology company’s stock worth $94,710,000 after purchasing an additional 816,822 shares in the last quarter. Finally, Macquarie Group Ltd. raised its holdings in shares of Repligen by 10.4% in the 4th quarter. Macquarie Group Ltd. now owns 965,962 shares of the biotechnology company’s stock worth $89,351,000 after purchasing an additional 91,083 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

The company has a current ratio of 15.56, a quick ratio of 14.09 and a debt-to-equity ratio of 0.25. The business’s fifty day moving average is $125.27 and its 200 day moving average is $111.55. The firm has a market capitalization of $7.91 billion, a P/E ratio of 126.04, a P/E/G ratio of 5.43 and a beta of 1.06.

Repligen Company Profile (NASDAQ:RGEN)

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Does the Dogs of the Dow strategy work?

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.